interleukin-8 and tanespimycin

interleukin-8 has been researched along with tanespimycin* in 5 studies

Trials

1 trial(s) available for interleukin-8 and tanespimycin

ArticleYear
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Dec-01, Volume: 14, Issue:23

    17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a benzoquinone ansamycin antibiotic with antiproliferative activity in several mouse xenograft models, including prostate cancer models. A two-stage phase II study was conducted to assess the activity and toxicity profile of 17-AAG administered to patients with metastatic, hormone-refractory prostate cancer.. Patients with at least one prior systemic therapy and a rising prostate-specific antigen (PSA) were eligible. Patients received 17-AAG at a dose of 300 mg/m2 i.v. weekly for 3 of 4 weeks. The primary objective was to assess the PSA response. Secondary objectives were to determine overall survival, to assess toxicity, and to measure interleukin-6, interleukin-8, and maspin levels and quality of life.. Fifteen eligible patients were enrolled. The median age was 68 years and the median PSA was 261 ng/mL. Patients received 17-AAG for a median number of two cycles. Severe adverse events included grade 3 fatigue (four patients), grade 3 lymphopenia (two patients), and grade 3 back pain (two patients). The median PSA progression-free survival was 1.8 months (95% confidence interval, 1.3-3.4 months). The 6-month overall survival was 71% (95% confidence interval, 52-100%).. 17-AAG did not show any activity with regard to PSA response. Due to insufficient PSA response, enrollment was stopped at the end of first stage per study design. The most significant severe toxicity was grade 3 fatigue. Further evaluation of 17-AAG at a dose of 300 mg/m2 i.v. weekly as a single agent in patients with metastatic, hormone-refractory prostate cancer who received at least one prior systemic therapy is not warranted.

    Topics: Aged; Antineoplastic Agents; Benzoquinones; Drug Resistance, Neoplasm; Humans; Immunoassay; Interleukin-6; Interleukin-8; Kaplan-Meier Estimate; Lactams, Macrocyclic; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Reverse Transcriptase Polymerase Chain Reaction; Serpins

2008

Other Studies

4 other study(ies) available for interleukin-8 and tanespimycin

ArticleYear
Hsp90 inhibition suppresses NF-κB transcriptional activation via Sirt-2 in human lung microvascular endothelial cells.
    American journal of physiology. Lung cellular and molecular physiology, 2016, 05-15, Volume: 310, Issue:10

    The ability of anti-heat shock protein 90 (Hsp90) drugs to attenuate NF-κB-mediated transcription is the major basis for their anti-inflammatory properties. While the molecular mechanisms underlying this effect are not clear, they appear to be distinct in human endothelial cells. We now show for the first time that type 2 sirtuin (Sirt-2) histone deacetylase binds human NF-κB target gene promoter and prevents the recruitment of NF-κB proteins and subsequent assembly of RNA polymerase II complex in human lung microvascular endothelial cells. Hsp90 inhibitors stabilize the Sirt-2/promoter interaction and impose a "transcriptional block," which is reversed by either inhibition or downregulation of Sirt-2 protein expression. Furthermore, this process is independent of NF-κB (p65) Lysine 310 deacetylation, suggesting that it is distinct from known Sirt-2-dependent mechanisms. We demonstrate that Sirt-2 is recruited to NF-κB target gene promoter via interaction with core histones. Upon inflammatory challenge, chromatin remodeling and core histone H3 displacement from the promoter region removes Sirt-2 and allows NF-κB/coactivator recruitment essential for RNA Pol II-dependent mRNA induction. This novel mechanism may have important implications in pulmonary inflammation.

    Topics: Acetylation; Animals; Benzoquinones; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; HSP90 Heat-Shock Proteins; Humans; Interleukin-8; Lactams, Macrocyclic; Lipopolysaccharides; Lung; Male; Mice, Inbred C57BL; Microvessels; Protein Processing, Post-Translational; Protein Transport; Signal Transduction; Sirtuin 2; Transcription Factor RelA; Transcriptional Activation

2016
Inhibition of RPE cell sterile inflammatory responses and endotoxin-induced uveitis by a cell-impermeable HSP90 inhibitor.
    Experimental eye research, 2011, Volume: 93, Issue:6

    Dying cells release pro-inflammatory molecules, functioning as cytokines to trigger cell/tissue inflammation that is relevant to disease pathology. Heat-shock protein 90 (HSP90) is believed to act as a danger signal for tissue damage once released extracellularly. Potential roles of HSP90 were explored in retinal pigment epithelial (RPE) inflammatory responses to necrosis. Cellular extracts can trigger ARPE-19 cell inflammatory responses, producing cytokines that lead to an increase in ARPE-19 cell monolayer permeability. Addition of recombinant HSP90β mimics the induction of chemokines IL-8 and MCP-1 in cultured RPE cells, suggesting that released HSP90 can incite RPE cell sterile inflammatory responses. Consistent with this, classical HSP90 inhibitors were shown to substantially reduce necrosis-induced cytokine production and permeability increases in ARPE-19 cells. Moreover, a cell-impermeable inhibitor, 17-N,N-dimethylaminoethylamino-17-demethoxy-geldanamycin-N-oxide, also efficiently inhibited necrosis-induced cytokine production and TNF-α/IL-1β-induced increase in ARPE-19 cell permeability in vitro and endotoxin-induced development of uveitis in vivo, suggesting that HSP90 can contribute to necrosis-induced RPE inflammatory responses. Collectively, our data identify HSP90 as a pro-inflammatory molecule in RPE cell sterile inflammatory responses.

    Topics: Animals; Anti-Inflammatory Agents; Benzoquinones; Cell Line; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Heterocyclic Compounds, 2-Ring; HSP90 Heat-Shock Proteins; Humans; Inflammation Mediators; Interleukin-1beta; Interleukin-8; JNK Mitogen-Activated Protein Kinases; Lactams, Macrocyclic; Lipopolysaccharides; Male; Necrosis; Permeability; Protein Kinase Inhibitors; Pyrazoles; Rats; Rats, Inbred Lew; Retinal Pigment Epithelium; Signal Transduction; Time Factors; Tumor Necrosis Factor-alpha; Uveitis

2011
Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.
    British journal of cancer, 2009, Nov-03, Volume: 101, Issue:9

    We determined how CXC-chemokine signalling and necrosis factor-kappaB (NF-kappaB) activity affected heat-shock protein 90 (Hsp90) inhibitor (geldanamycin (GA) and 17-allylamino-demethoxygeldanamycin (17-AAG)) cytotoxicity in castrate-resistant prostate cancer (CRPC).. Geldanamycin and 17-AAG toxicity, together with the CXCR2 antagonist AZ10397767 or NF-kappaB inhibitor BAY11-7082, was assessed by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay in two CRPC lines, DU145 and PC3. Flow cytometry quantified apoptotic or necrosis profiles. Necrosis factor-kappaB activity was determined by luciferase readouts or indirectly by quantitative PCR and ELISA-based determination of CXCL8 expression.. Geldanamycin and 17-AAG reduced PC3 and DU145 cell viability, although PC3 cells were less sensitive. Addition of AZ10397767 increased GA (e.g., PC3 IC(20): from 1.67+/-0.4 to 0.18+/-0.2 nM) and 17-AAG (PC3 IC(20): 43.7+/-7.8 to 0.64+/-1.8 nM) potency in PC3 but not DU145 cells. Similarly, BAY11-7082 increased the potency of 17-AAG in PC3 but not in DU145 cells, correlating with the elevated constitutive NF-kappaB activity in PC3 cells. AZ10397767 increased 17-AAG-induced apoptosis and necrosis and decreased NF-kappaB activity/CXCL8 expression in 17-AAG-treated PC3 cells.. Ansamycin cytotoxicity is enhanced by inhibiting NF-kappaB activity and/or CXC-chemokine signalling in CRPC cells. Detecting and/or inhibiting NF-kappaB activity may aid the selection and treatment response of CRPC patients to Hsp90 inhibitors.

    Topics: Apoptosis; Benzoquinones; Cell Line, Tumor; Cell Survival; HSP90 Heat-Shock Proteins; Humans; Interleukin-8; Lactams, Macrocyclic; Male; Necrosis; NF-kappa B; Nitriles; Orchiectomy; Prostatic Neoplasms; Receptors, Interleukin-8B; Rifabutin; Signal Transduction; Sulfones

2009
Mechanisms of Legionella pneumophila-induced interleukin-8 expression in human lung epithelial cells.
    BMC microbiology, 2007, Nov-22, Volume: 7

    Legionella pneumophila is a facultative intracellular bacterium, capable of replicating within the phagosomes of macrophages and monocytes, but little is known about its interaction with human lung epithelial cells. We investigated the effect of L. pneumophila on the expression of interleukin-8 (IL-8) in human A549 alveolar and NCI-H292 tracheal epithelial cell lines.. Infection of L. pneumophila strain, but not heat-killed strain, resulted in upregulation of IL-8. IL-8 mRNA expression was induced immediately after the infection and its signal became gradually stronger until 24 h after infection. On the other hand, IL-8 expression in A549 cells infected with L. pneumophila lacking a functional type IV secretion system was transient. The IL-8 expression was slightly induced at 16 h and increased at 24 h after infection with flagellin-deficient Legionella. Activation of the IL-8 promoter by L. pneumophila infection occurred through the action of nuclear factor-kappaB (NF-kappaB). Transfection of dominant negative mutants of NF-kappaB-inducing kinase, IkappaB kinase and IkappaB inhibited L. pneumophila-mediated activation of IL-8 promoter. Treatment with hsp90 inhibitor suppressed L. pneumophila-induced IL-8 mRNA due to deactivation of NF-kappaB.. Collectively, these results suggest that L. pneumophila induces activation of NF-kappaB through an intracellular signaling pathway that involves NF-kappaB-inducing kinase and IkappaB kinase, leading to IL-8 gene transcription, and that hsp90 acts as a crucial regulator in L. pneumophila-induced IL-8 expression, presumably contributing to immune response in L. pneumophila. The presence of flagellin and a type IV secretion system are critical for Legionella to induce IL-8 expression in lung epithelial cells.

    Topics: Benzoquinones; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Epithelial Cells; Gene Expression Regulation; HSP90 Heat-Shock Proteins; Humans; Interleukin-8; Lactams, Macrocyclic; Legionella pneumophila; Lung; NF-kappa B; NF-kappaB-Inducing Kinase; Phosphorylation; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Transcription, Genetic; Transfection

2007